M Ippolito Selected Research

Viral Pneumonia

1/2021

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M Ippolito Research Topics

Disease

4	COVID-19 07/2021 - 07/2020
2	Neoplasms (Cancer) 01/2022 - 01/2010
1	Cholangiocarcinoma 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Malignant Mesothelioma 01/2022
1	Mesothelioma 01/2022
1	Sepsis (Septicemia) 01/2021
1	Viral Pneumonia 01/2021
1	Osteoporosis 11/2004
1	Glucose Intolerance 09/2001
1	Insulin Resistance 09/2001
1	Dyslipidemias (Dyslipidemia) 09/2001
1	Hyperglycemia 12/2000

Drug/Important Bio-Agent (IBA)

2	tocilizumab (atlizumab)FDA Link 01/2021 - 01/2021
2	Glucose (Dextrose)FDA LinkGeneric 09/2001 - 12/2000
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2010
1	Oncogene Proteins (Oncogene Protein)IBA 01/2010
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2010
1	Fenofibrate (CiL)FDA LinkGeneric 09/2001
1	LipidsIBA 09/2001
1	PPAR alphaIBA 09/2001
1	Cortisone FDA Link 12/2000
1	Hydrocortisone (Cortisol)FDA LinkGeneric 12/2000

Therapy/Procedure

3	Therapeutics 01/2022 - 11/2004
2	Continuous Positive Airway Pressure 07/2021 - 07/2020
1	Drug Therapy (Chemotherapy) 01/2022